论文部分内容阅读
目的研究分析采用采用恩替卡韦治疗高病毒量乙型病毒性肝炎(HBV)感染合并肺结核肝损害的治疗效果。方法选择本院从2011年10月~2013年10月收治的75例高病毒量HBV合并肺结核肝损害患者,将所有患者随机分为A、B、C三组,每组各25例,A组在化疗前2周给予恩替卡韦治疗,B组患者在化疗开始的同时给予恩替卡韦治疗,C组患者仅仅进行抗结核治疗。观察对比这三组患者在治疗后的肝损害发生率和肝功能指标变化情况。结果 A组和B组患者在治疗后的肝损伤发生率情况明显优于C组患者,差异具有统计学意义(P<0.05);A组和B组患者在治疗后与治疗前的肝功能无改变,C组患者ALT、AST水平与治疗前相比显著升高,与A组和B组相比,差异具有统计学意义(P<0.05)。结论对于高病毒量HBV感染合并肺结核肝损害在化疗前给予恩替卡韦具有比较好的治疗效果,值得广泛运用。
Objective To study and analyze the therapeutic effect of entecavir in the treatment of hepatitis B virus (HBV) infection complicated with tuberculosis liver damage with high viral load. Methods From July 2011 to October 2013 in our hospital, 75 patients with high viral HBV infection complicated with tuberculosis liver damage were selected. All patients were randomly divided into three groups A, B and C, with 25 cases in each group. Group A Entecavir was given 2 weeks prior to chemotherapy, while entecavir was given in group B at the beginning of chemotherapy and in group C only on anti-TB. Observed and compared these three groups in the incidence of liver damage after treatment and changes in liver function indicators. Results The incidence of liver injury after treatment in group A and group B was significantly better than that in group C (P <0.05). The liver function of group A and group B after treatment was significantly lower than that before treatment Compared with those before treatment, the levels of ALT and AST in group C were significantly higher than those in group A and group B (P <0.05). Conclusion It is worth widely using for the treatment of patients with high viral load HBV infection and liver damage caused by entecavir before chemotherapy.